STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced that Alexandra Sapetschnig, Group Leader at STORM, will present late breaking data on STORM’s METTL1 inhibitors at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, held 5-10 April 2024.
The presentation entitled ‚First-in-class inhibitors of the tRNA methyltransferase METTL1 for the treatment of cancer‘ details the discovery of STORM’s first-in-class inhibitors of METTL1 tRNA methyltransferase and supporting evidence of its potential as a novel target for anti-cancer drugs.
Details of the late breaking poster presentation are as follow:
Poster Title: First-in-class inhibitors of the tRNA methyltransferase METTL1 for the treatment of cancer
Presenter: Alexandra Sapetschnig, Group Leader at STORM
Authors: Alexandra Sapetschnig1, Beth Thomas1, Eliza Yankova2, Harry Fischl1, Aleksandra Azevedo1, Sarah Bucknell1, Richard Fosbeary1, Sapphire Sawyer1, Sian Evans2, Carmen Livi1, Byron Andrews1, Jack Rogan1, Natalie Webster1, Matthew Fyfe1, Konstantinos Tzelepis2, Oliver Rausch1
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Session Date and Time: Monday Apr 8, 2024 1:30 PM – 5:00 PM
Location: Poster Section 52
Poster Board Number: 17
Abstract Presentation Number: LB171
1 Storm Therapeutics Ltd, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom
2 Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, United Kingdom
Late breaking abstracts will be available in an online itinerary planner here on the 5 April and will be available in on online only supplement to the AACR journal Cancer Research one month after the conference.
https://www.abstractsonline.com/pp8/#!/20272/presentation/10547
